Chapter II · 5 min read

The Demand

Search and social velocity by treatment — with #looksmaxxing accelerating 6.2×, the fastest-rising signal in the dataset, often months ahead of the procedure demand it precedes.

Sources in this chapter
[1]SEMrush / Keyword Planner[2]TikTok / IG analytics (modeled)[3]Medica Depot / Galderma[4]FAIR Health[5]FDA filings
~246k
Monthly medspa local-intent searches (modeled aggregate) — booking-ready, not research.
201k
Monthly Botox searches; lip filler adds 110k.
6.2×
#looksmaxxing — fastest-accelerating trend in our dataset.
6
Regulatory catalysts reshaping demand through 2028.

~246,000 people search for a medspa near them every month.

Botox follows at 201k. Lip filler at 110k. These aren't research queries — “near me” and “cost” modifiers signal bottom-of-funnel intent much more than awareness browsing.

~246k

Medspa local-intent searches/mo (modeled aggregate)

Modeled

201k

"Botox" monthly searches

Vendor-reported

Modeled aggregate of medspa local-intent queries; Google Keyword Planner / SEMrush anchors, 2024–2025. (Exact-match “medspa near me” ≈ 33k/mo.)

Velocity matters more than volume.

#looksmaxxing is accelerating at 6.2× — the fastest trend in our dataset. These aren't fringe curiosities; they're category-forming movements that can precede procedure demand shifts by months.

TikTok + Instagram trend analytics, 12-month velocity window

The next wave is already here.

Biostimulators are displacing traditional HA fillers. Polynucleotides (salmon-DNA injections) are mainstream in Korea and entering the US. Skin boosters like Profhilo sit between filler and topical — an entirely new procedural category.

We track 14 emerging treatment trends by confidence and proximity.

10

High-confidence trends

External study

14

Total emerging trends tracked

External study

Medica Depot 2024, Galderma consensus, Loma Health, Revance filings

Six catalysts will reshape the next three years.

A sixth neurotoxin compressing pricing. A triple-agonist driving facial restoration demand. A compounding sunset forcing clinics to pivot. These aren't hypothetical — they have FDA filing dates and sponsor timelines.

FDA filings, Eli Lilly / Revance / Hugel SEC disclosures, PRS Global Open

New Signalobserved + modeled · Mirror original

The GLP-1 Aesthetic Dividend

The popular take is that weight-loss drugs are emptying the gyms. They aren't — US gyms hit a record 77M members in 20247. What GLP-1s are actually collapsing is the structured-diet industry (Weight Watchers filed Chapter 11 in 2025, members 4.4M → 2.6M)6 — and, more usefully for medspas, they are manufacturing a brand-new aesthetic patient who never existed before.

6% → 12%
US adults on a GLP-1 — doubled in 18 months
[1] KFF poll, Nov 2025
63%
of GLP-1 aesthetic patients are NEW to medical aesthetics
[2] McKinsey, May 2025 (174 providers)
61% / 50%
develop midface volume loss / skin laxity
[3] Allergan Aesthetics, Mar 2026
+50%
rise in facial fat-grafting (the 'Ozempic face' fix)
[4] AAFPRS 2024 Trends Survey

The conversion funnel

ObservedModeled
~31MUS adults on a GLP-1 today
12% of adults · KFF Nov 2025
~50%develop a visible aesthetic concern
skin laxity / midface volume loss · Allergan 2026
~25%act on it inside the aesthetic system
modeled · above the 11% post-bariatric surgical floor, below McKinsey's 40% spend-up
~3.9Mnet-new / upgraded aesthetic patients
31M × 50% × 25%
~$7B/yrnet-new medspa demand pool
3.9M × ~$1,800/yr (AmSpa $527 × 3.4 visits)

The 50% effect-rate and the $1,800 unit are observed; the ~25% act-rate is the one modeled lever — bracketed 15–35%, which sets the $4–10B range.

The metric — and the 2028 step-up

~$0.6Bnet-new medspa demand
per 1 point of US GLP-1 adoption. Adoption doubled in 18 months — this is the elasticity that compounds.
$4–10B
2026
$8–17B
2028
2026: 12% adoption · semaglutide/tirzepatide (~15–21% loss)
2028: ~18% adoption (projected) · retatrutide (~24–28% loss)

Retatrutide (~24–28% weight loss vs ~21% for tirzepatide; FDA est. 2027–28)5 deepens the effect-rate as adoption keeps climbing — the dividend doesn't just grow, it steps up.

What this means

Three readings of the same data.

If you run a clinic
Read demand before it hits the calendar.
  • 'Near me' and 'cost' searches are booking-ready — capture them with intent-matched pages.
  • Social velocity (looksmaxxing, salmon-DNA) predicts procedure volume 12–18 months out.
  • Six regulatory catalysts will move pricing and demand through 2028 — plan menu shifts now.
If you evaluate the space
Structural, durable demand tailwinds.
  • 246k monthly 'med spa near me' searches — a large, growing top of funnel.
  • GLP-1 scripts +587% (2019–24) is reshaping adjacent aesthetic demand.
  • Emerging categories (biostimulators, polynucleotides) extend the runway.
If you advise operators
Position around the next wave, not the last one.
  • Track the six catalysts — Letybo (6th neurotoxin), Daxxify, retatrutide.
  • Filler is softening (~1% YoY); biostimulators and skin boosters are rising.
  • Match content to the searches that actually convert.
Mirror preview · Chapter 2 · What Patients Want Next

Next step after the demand signals

Search interest only matters when patients can self-qualify.

A treatment trend does not become revenue just because people search for it. Patients still need to understand candidacy, tradeoffs, expected results, and whether the next step is worth their time. Mirror helps answer those questions before the consult.

Candidacy prompts
Result expectations
Consult-ready lead context

The Atlas stays free either way. Mirror is for clinics that want this research to turn into a stronger consult path on their own site.

Patient path
Mirror
What the visitor is thinking

Am I a candidate, and what would a realistic result look like?

What Mirror adds

A trend becomes useful when it reduces uncertainty.

QuestionPreviewConsult
Consult-ready next step

Mirror gives the patient enough confidence to move forward.